Product Details

Felvizumab is a humanized monoclonal antibody designed to target the Respiratory Syncytial Virus (RSV), which is responsible for respiratory infections, particularly in young children and the elderly. It works by binding to the F protein of RSV, which plays a critical role in the virus's ability to infect cells. Felvizumab is often classified as a biosimilar, meaning it is a version of a previously approved antibody with highly similar properties, developed for research and therapeutic purposes​